Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

Richard E. Pratley, M. S. Kipnes, P. R. Fleck, C. Wilson, Q. Mekki, P. Castano, J. Cuadrado, L. Maffei, F. Massari, G. Sposetti, M. Ulla, S. Colagiuri, M. dEmden, D. O'Neal, J. Prins, A. Roberts, M. Dinato, A. Forti, J. Gross, C. HayashidaJ. Neto, R. Rea, L. Aguirre, G. Gonzalo, F. Munizaga, F. Luna-Sevez, A. Granandos-Fuentes, L. Ramirez-Roca, F. Sanchez-Morales, K. Prasanna Kumar, N. Rais, V. Seshiah, N. Thomas, M. Viswanathan, V. Viswanathan, C. Dueñas-Garcia, G. Gonzalez-Galvez, C. Gonzalez-Villalpando, F. Mar-Arevalo, E. Morales-Villegas, F. Salinas-Gonzalez, A. Dees, A. Deijl, A. Dissanayake, J. Krebs, R. Scott, S. Young, H. Arbañil, S. Corigliano, L. Gonzales, A. Luna, G. Molina, L. More, J. Kuleta, J. Loba, P. Mader, A. Mikolajczyk-Swatko, J. Sawer-Szewczyk, A. Stankiewicz, Z. Stepien, W. Boyd, L. Burgess, G. Ellis, P. Joshi, L. De Teresa, T. Hall, C. McKinnon, J. Ryan, J. Barrera, G. Bonabi, C. Chappel, W. Cheatham, L. Cohen, C. Corder, S. Elliott, D. Fitz-Patrick, M. Hassman, P. Hollander, D. Hurley, C. Jones, M. Kipnes, W. Koppel, S. Landgarten, A. Lewin, M. Lindley, R. Lipetz, T. Littlejohn, J. Lucas, G. Mark, R. Marple, E. Mattson, S. Mayeda, M. McAdoo, D. Morin, J. Mullen, J. Neutel, P. Norwood, S. Oates, A. Odugbesan, R. Pratley, K. Pudi, M. Rendell, K. Rock, J. Rosenstock, K. Sall, D. Santram, M. Seidner, T. Smith, M. Soboeiro, J. Sparks, R. Stegemoller, L. Taber, H. Wadsworth, J. Wahle, R. Weinstein, J. Wilker

Research output: Contribution to journalArticlepeer-review

133 Scopus citations


Aim: To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in combination with glyburide in patients with type 2 diabetes inadequately controlled by sulphonylurea monotherapy. Methods: After a 2-week screening period, adult patients 18-80 years of age entered a 4-week run-in/stabilization period in which they were switched from their own sulphonylurea medication to an equivalent dose of glyburide (open label) plus placebo (single blind). After the run-in period, patients were randomly assigned to double-blind treatment with alogliptin 12.5 mg (n = 203), alogliptin 25 mg (n = 198), or placebo (n = 99) for 26 weeks. The primary end-point was change from baseline to week 26 in glycosylated haemoglobin (HbA1c). Secondary end-points included clinical response rates and changes in fasting plasma glucose, β-cell function (fasting proinsulin, insulin, proinsulin/insulin ratio, and C-peptide, and homeostasis model assessment β-cell function), body weight, and safety end-points [adverse events (AEs), clinical laboratory tests, vital signs and electrocardiographic readings]. Results: The study population had a mean age of 57 years and a mean disease duration of 8 years; it was well balanced for gender (52% women) and was mainly white (71%). The mean baseline HbA1c was approximately 8.1% in each group. Significantly greater least squares (LS) mean reductions in HbA1c were seen at week 26 with alogliptin 12.5 mg (-0.38%) and 25 mg (-0.52%) vs. placebo (+0.01%; p <0.001), and more patients in the alogliptin 25-mg group had HbA1c levels ≤7.0% at week 26 (34.8%, p = 0.002) vs. placebo (18.2%). Proportionately more patients in the alogliptin 12.5 mg (47.3%) and 25 mg (50.5%) groups had an HbA1c reduction ≥0.5% from baseline compared with patients in the placebo group (26.3%; p <0.001). Minor improvements in individual markers of β-cell function were seen with alogliptin, but no significant treatment group differences were noted relative to placebo. Minor LS mean changes in body weight were noted across groups (placebo, -0.20 kg; alogliptin 12.5 mg, +0.60 kg; alogliptin 25 mg, +0.68 kg). AEs were reported for 63-64% of patients receiving alogliptin and 54% of patients receiving placebo. Few AEs were treatment limiting (2.0-2.5% across groups), and serious AEs (2.0-5.6%) were infrequent, similar across groups, and generally considered not related to treatment. The incidences of hypoglycaemia for placebo, alogliptin 12.5mg and alogliptin 25 mg groups were 11.1, 15.8 and 9.6% respectively. Conclusions: In patients with type 2 diabetes inadequately controlled by glyburide monotherapy, the addition of alogliptin resulted in clinically significant reductions in HbA1c without increased incidence of hypoglycaemia.

Original languageEnglish (US)
Pages (from-to)167-176
Number of pages10
JournalDiabetes, Obesity and Metabolism
Issue number2
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy'. Together they form a unique fingerprint.

Cite this